XLO Stock Analysis: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$8.90
-0.04 (-0.45%)
▼
5d:
+6.71%
30d:
+3.79%
90d:
+13.23%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $8.90, which is considered extended relative to its 30-day fair value range of $7.99 to $8.62. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.4) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.57, while resistance sits at $9.30.
Market Sentiment: XLO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+124.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.57, while resistance sits at $9.30.
Market Sentiment: XLO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+124.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.99 -
$8.62
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 124.7% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$7.99 -
$8.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.57
Resistance Level
$9.30
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.44
Wall Street Target
$20.00
(+124.7%)
Revenue Growth (YoY)
331.7%
Profit Margin
-58.5%
PE vs Historical
-3.4 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 11:22 PM ET
Data refreshes hourly during market hours. Next update: 12:22 AM
Data refreshes hourly during market hours. Next update: 12:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$8 | 60 HOLD |